Replacing two chemotherapy blocks with blinatumomab raised event-free survival in high-risk childhood ALL

Design

Randomised controlled trial (planned interim analysis)

Population

709 children with newly diagnosed high-risk B-cell ALL

Primary outcome

Event-free survival

Effect

4-year EFS 83.0% vs 70.3%; HR 0.51 (95% CI 0.35–0.73)

The AIEOP-BFM ALL 2017 trial randomised 709 children with newly diagnosed high-risk B-cell acute lymphoblastic leukaemia, after consolidation, to two cycles of blinatumomab — a CD19-directed bispecific T-cell engager — or two cycles of conventional intensive chemotherapy.

At a planned interim analysis (median follow-up 2.9 years), estimated 4-year event-free survival was 83.0% with blinatumomab and 70.3% with chemotherapy (HR 0.51, 95% CI 0.35–0.73). Treatment-related infection fell from 69.4% to 23.9%, and life-threatening adverse events from 4.7% to 0.5% (one fatal event with blinatumomab). Neurotoxicity was more frequent (12.0% vs 3.2%), and grade 2 or higher cytokine release syndrome occurred in 1.1%.

This is the rare trial where the less toxic option is also more effective, and it is likely to move blinatumomab into frontline protocols for high-risk paediatric B-ALL. Access and cost will limit uptake in India, where the drug is expensive.

• Expect frontline paediatric high-risk B-ALL protocols to incorporate blinatumomab in place of intensive chemotherapy blocks.
• Anticipate about one in eight fewer relapses or events at four years.
• Expect far fewer serious infections — nearly two in three children had infections with chemotherapy versus one in four with blinatumomab.
• Monitor for neurotoxicity, which was about four times more common with blinatumomab.
• Plan early for drug access and cost, including support schemes, where blinatumomab is not routinely funded.

Why it matters

It shows immunotherapy can replace, not just add to, toxic chemotherapy in newly diagnosed childhood leukaemia.

Don't overread it

This is an interim analysis at median 2.9 years; overall survival and long-term late effects are not yet reported.

The statistics, in plain English

A hazard ratio of 0.51 means the rate of relapse, resistance, second cancer or death was roughly halved. This comes from a planned interim analysis, which can overestimate benefit if stopped early, but the confidence interval (0.35–0.73) is well away from 1.0.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.